Cinnamon’s Culinary Safety: No Significant Drug Interaction Risk for Common Medications
A clinical pharmacology study has investigated the potential interaction between a common cinnamon supplement and drugs metabolized by the liver enzyme CYP2A6. Researchers administered a standardized cinnamon product to healthy adults alongside single doses of nicotine and the breast cancer drug letrozole, both known CYP2A6 substrates. Pharmacokinetic analysis revealed that the cinnamon supplement did not significantly alter the plasma concentration profiles or overall exposure of either drug. The geometric mean ratios for area-under-the-curve were close to 1, indicating no clinically meaningful interaction. This suggests that typical dietary consumption of cinnamon is unlikely to interfere with the metabolism and efficacy of medications processed through this specific enzymatic pathway.
Why it might matter to you: For clinicians managing patients with breast cancer or those using nicotine replacement therapy, this study provides evidence-based reassurance regarding concomitant cinnamon use. It addresses a common concern in patient counseling about dietary supplements and prescription drug safety. This finding can help streamline clinical guidance, potentially reducing unnecessary dietary restrictions for patients on these specific therapies.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
